Reshoring U.S. Pharma Manufacturing: The United States is experiencing a major resurgence in pharmaceutical manufacturing. Companies are investing tens of billions of dollars to build and expand facilities across the country—from Virginia and Indiana to Texas, Florida, Wisconsin, Delaware, and even Puerto Rico. This wave of investment is more than corporate expansion; it is a strategic reshaping of the nation’s pharmaceutical landscape.
Lilly Leads the Reshoring Wave
Eli Lilly is at the forefront of this reshoring movement. Its investments include:
West Creek, Virginia – $5 billion facility for cancer and autoimmune drug ingredients.
Generation Park, Houston, Texas – $6.5 billion plant focused on active pharmaceutical ingredient (API) production for small molecules.
LEAP District, Indiana – $4.5 billion “Medicine Foundry” integrating small molecules, biologics, and genetic medicines.
Puerto Rico – $1.2 billion investment reviving pharmaceutical manufacturing on the island.
Pleasant Prairie, Wisconsin – multibillion-dollar expansion strengthening domestic production.
These projects create thousands of construction and permanent jobs while producing a broad spectrum of therapies, from traditional drugs to advanced biologics and genetic medicines. Lilly’s approach shows how a company can combine flexibility, innovation, and scale to meet both domestic and global demand.
Other Major Players Are Joining
The reshoring trend is widespread. AstraZeneca has committed $4.5 billion to a Virginia facility producing weight/metabolic and oncology therapies. Merck is developing two major U.S. sites: a $3 billion pharmaceutical manufacturing plant in Elkton, Virginia, and a $1 billion biotech facility in Wilmington, Delaware. These investments reinforce the U.S. as a hub for both APIs and advanced biologics.
Specialty and contract manufacturers are also reshoring:
Lupin – $250 million facility in Coral Springs, Florida, expanding respiratory drug production.
AbbVie – $70 million Worcester Bioresearch Center expansion and $195 million API facility in North Chicago.
Genentech – $700 million Holly Springs site for biologics.
Together, these projects represent a nationwide network of manufacturing capacity, stretching from the East Coast to the Gulf Coast and Puerto Rico.
Reshoring U.S. Pharma Manufacturing: Why It Matters
This reshoring trend has broad national significance:
Supply-chain resilience – domestic production reduces dependence on overseas suppliers and protects against future disruptions.
Innovation acceleration – co-locating R&D and manufacturing enables faster development of new therapies.
Economic growth – tens of thousands of construction and permanent jobs flow into local communities, strengthening the U.S. workforce.
Global leadership – investing in advanced manufacturing technologies ensures the U.S. remains a hub for cutting-edge pharmaceuticals, from biologics to novel cancer therapies.
Building America’s Pharmaceutical Future
Across the U.S.—from Puerto Rico and Delaware to Texas, Virginia, and Wisconsin—these investments are bringing jobs, boosting local economies, and ensuring critical medicines are made at home. Reshoring isn’t just corporate strategy; it strengthens supply chains, public health, and national resilience. Each new facility means thousands of construction and skilled jobs, vibrant communities, and a nation positioned as a global hub for advanced therapies.
By producing medicines on American soil, the country is preparing for future health emergencies while creating economic opportunities that touch the lives of millions of Americans every day.
